
## Alexandra Leary

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3373933/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 2018, 379, 2495-2505.	13.9	1,854
2	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1949-1961.	6.3	1,261
3	Endometrial cancer. Lancet, The, 2016, 387, 1094-1108.	6.3	1,213
4	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 75-87.	5.1	975
5	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Journal of Clinical Oncology, 2020, 38, 3388-3397.	0.8	398
6	Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncology, The, 2016, 17, e240-e253.	5.1	206
7	The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chinese Journal of Cancer, 2015, 34, 4-16.	4.9	162
8	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature Communications, 2021, 12, 2487.	5.8	116
9	Renal toxicities associated with pembrolizumab. CKJ: Clinical Kidney Journal, 2019, 12, 81-88.	1.4	101
10	Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecologic Oncology, 2021, 163, 274-280.	0.6	59
11	CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clinical Cancer Research, 2020, 26, 4625-4632.	3.2	47
12	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. Journal of the National Cancer Institute, 2021, 113, 1212-1220.	3.0	47
13	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nature Communications, 2022, 13, 1373.	5.8	47
14	HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. Cancers, 2021, 13, 44.	1.7	40
15	Immune checkpoint inhibitors in ovarian cancer: where do we stand?. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110398.	1.4	36
16	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. Modern Pathology, 2018, 31, 1851-1861.	2.9	35
17	Surgical Outcomes After Debulking Surgery for Intraabdominal Ovarian Growing Teratoma Syndrome: Analysis of 38 Cases. Annals of Surgical Oncology, 2015, 22, 964-970.	0.7	34
18	Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. Clinical Cancer Research, 2019, 25, 5342-5350.	3.2	33

ALEXANDRA LEARY

#	Article	IF	CITATIONS
19	Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types. Gynecologic Oncology Reports, 2017, 22, 21-25.	0.3	31
20	Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications. International Journal of Cancer, 2018, 143, 8-15.	2.3	28
21	Results from a Monocentric Longâ€Term Analysis of 23 Patients with Ovarian Sertoli‣eydig Cell Tumors. Oncologist, 2019, 24, 702-709.	1.9	28
22	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. Journal of Clinical Oncology, 2020, 38, 3494-3505.	0.8	28
23	Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors. Gynecologic Oncology, 2016, 142, 452-457.	0.6	23
24	Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer. Cancer Immunology, Immunotherapy, 2021, 70, 519-531.	2.0	22
25	Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). JNCI Cancer Spectrum, 2020, 4, pkaa026.	1.4	21
26	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. European Journal of Cancer, 2022, 166, 87-99.	1.3	21
27	Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. PLoS ONE, 2018, 13, e0204973.	1.1	18
28	Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape Gynecologic Oncology, 2021, 160, 279-284.	0.6	18
29	Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers. Oncologist, 2018, 23, 324-327.	1.9	17
30	Should We Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer?. Anticancer Research, 2019, 39, 2919-2926.	0.5	14
31	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. Gynecologic Oncology, 2020, 159, 101-111.	0.6	14
32	Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study Journal of Clinical Oncology, 2021, 39, 5513-5513.	0.8	13
33	Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). Gynecologic Oncology, 2020, 159, 256-263.	0.6	11
34	A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study. Gynecologic Oncology, 2022, 165, 30-39.	0.6	11
35	Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer. Investigational New Drugs, 2019, 37, 693-701.	1.2	9
36	Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1998-2008.	3.3	9

ALEXANDRA LEARY

#	Article	IF	CITATIONS
37	Cervical Cancer and Fertility-Sparing Treatment. Journal of Clinical Medicine, 2021, 10, 4825.	1.0	9
38	Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial. Gynecologic Oncology, 2021, 163, 563-568.	0.6	9
39	Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours. British Journal of Cancer, 2020, 122, 564-568.	2.9	8
40	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. International Journal of Gynecological Cancer, 2021, 31, 949-958.	1.2	7
41	Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy. Clinical and Experimental Metastasis, 2016, 33, 775-785.	1.7	6
42	Optimizing Local Control in Highâ€Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment. Oncologist, 2017, 22, 182-188.	1.9	6
43	A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer. Gynecologic Oncology, 2020, 159, 534-538.	0.6	5
44	Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. British Journal of Cancer, 2022, 127, 79-83.	2.9	5
45	ls uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?. Gynecologic Oncology Reports, 2017, 22, 52-54.	0.3	1